Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.82−0.02 (-0.52%)
Close on Nov 18, 2026Market cap $692.86MP/E –Yield –
Prime Medicine revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Prime Medicine's revenue for the twelve months ending Dec 31, 2025 was $4.63M, up 55.3% year over year. For fiscal 2025 it was $4.63M, up 55.3% from the year before. The highest annual figure on record is $5.21M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.63M | +55.3% |
| FY2024 | Dec 31, 2024 | $2.98M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $5.21M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $838.00K | -61.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.23M | +486.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.12M | – |
| Q1 FY2025 | Mar 31, 2025 | $1.45M | +146.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.18M | – |
| Q3 FY2024 | Sep 30, 2024 | $209.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $591.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | – |
See a number that looks wrong?